Table 1.
Summary demographics and baseline characteristics of enrolled subjects.
| MELD 11-20 group (n=9) | MELD 21-28 group (n=9) | |
|---|---|---|
| Age (years) | 51.5 ± 9.7 | 46.8 ± 9.9 |
| Female (%) | 22.2% (2/9) | 44.4% (4/9) |
| Race | 100% White (9/9) | 89.9% white (8/9), 11.1% American Indian (1/9) |
| Alcohol consumption (g/day) | 175 ± 91.5 | 145.5 ± 102.5 |
| Hospitalized at screening (%) | 7/9 (77.8%) | 6/9 (66.7%) |
| Days hospitalized prior to 1st dose | 4.2 ± 2.7 | 2.1 ± 2.0 |
| Steroids use prior to first dose (%) | 11.1% (1/9) | 33.3% (3/9) |
| Baseline infection | 0% (0/9) | 0% (0/9) |
| WBC count (x109) | 9.4 ± 6.9 | 10.7 ± 5.6 |
| Creatinine (mg/dL) | 0.81 ± 0.32 | 0.77 ± 0.19 |
| AST (IU/L) | 151.5 ± 83.5 | 130.7 ± 67.0 |
| ALT (IU/L) | 84.1 ± 38.0 | 66.5 ± 47.2 |
| Bilirubin (mg/dL) | 6.8 ± 3.8 | 14.5 ± 8.6 |
| Bilirubin at day 7 (mg/dL) | 4.2 ± 3.8 | 6.1 ± 2.5 |
| Albumin (g/dL) | 2.8 ± 0.5 | 3.0 ± 0.7 |
| INR | 1.4 ± 0.3 | 2.0 ± 0.3 |
| C-reactive protein (g/dL) | 31.6 ± 27.2 | 12.4 ± 8.0 |
| MELD | 17.3 ± 2.3 | 23.8 ± 2.7 |
| Hepatic encephalopathy (%) | 2/9 (22.2%) | 1/9 (11.1%) |
| Known cirrhosis (%) | 3/9 (33.3%) | 9/9 (100%) |
| Liver biopsy (%) | 2/9 (22.2%) | 1/9 (11.1%) |
Data are presented as mean ± SD, or percentages.